Bryant Ranch Prepack

Pharmaceutical company88 products tracked

products tracked

4,705,846

total reports

788

recalls on record

68.5%

serious overall

Products

showing 88 of 88

Product	Approved	Reports ↓	Top signal	Recalls
furosemide —	1983	393,086	Cardiac failure congestive	14
ergocalciferol —	1953	374,035	Sinusitis	2
gabapentin —	2000	359,779	Drug ineffective for unapproved indication	25
pregabalin —	2004	267,198	Withdrawal syndrome	10
atorvastatin calcium —	1996	243,012	Type 2 diabetes mellitus	65
ibuprofen oral —	—	195,098	Chronic kidney disease	17
quetiapine —	1997	188,609	Type 2 diabetes mellitus	12
adapalene —	2007	181,371	Chemical burn of skin	4
allopurinol —	1984	153,758	Gout	7
atenolol —	1981	133,343	Bradycardia	5
mycophenolate mofetil —	1995	131,745	Transplant rejection	9
fluoxetine —	2002	129,920	Serotonin syndrome	11
venlafaxine hydrochloride —	1993	129,795	Serotonin syndrome	0
fluoxetine hydrochloride —	2002	124,895	Serotonin syndrome	1
acyclovir —	1982	112,882	Plasma cell myeloma	19
fluticasone propionate and salmeterol —	—	99,522	Asthma	1
hydrocodone bitartrate —	1983	95,444	Learning disability	22
metoprolol succinate —	1992	83,951	Atrial fibrillation	27
digoxin —	1954	70,807	Economic problem	7
glatiramer —	1996	61,926	Multiple sclerosis relapse	4
glatiramer acetate —	1996	60,482	Multiple sclerosis relapse	4
glipizide —	1994	60,122	Blood glucose decreased	14
metoprolol succinate er tablets —	—	60,053	Atrial fibrillation	0
hydrocodone bitartrate and acetaminophen —	—	55,871	Learning disability	14
hydroxyzine —	1981	49,201	Completed suicide	24
dextroamphetamine —	1955	47,736	Pre-existing condition improved	47
lamivudine —	2011	46,910	Viral mutation identified	5
dextroamphetamine sulfate —	2001	44,739	Pre-existing condition improved	46
mirabegron —	2012	37,628	Urinary incontinence	0
temazepam —	1981	37,190	Completed suicide	0
clindamycin —	1972	37,185	Chronic kidney disease	44
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate —	—	34,483	Pre-existing condition improved	12
diltiazem hydrochloride —	1982	34,050	Atrial fibrillation	15
clindamycin phosphate —	1972	33,218	Chronic kidney disease	11
nebivolol —	2007	33,035	Bradycardia	7
bumetanide —	1994	25,624	Fluid retention	6
glyburide —	1984	24,178	Hypoglycaemia	4
progesterone —	1974	22,513	Temperature regulation disorder	100
exemestane —	1999	21,059	Breast cancer metastatic	2
temozolomide —	1999	20,653	Glioblastoma	0
zidovudine —	1989	19,859	Lipodystrophy acquired	0
pravastatin sodium —	1991	19,328	Eye pain	17
erythromycin —	1967	18,910	Drug hypersensitivity	14
ropinirole —	1997	18,237	Restless legs syndrome	13
sotalol hydrochloride —	1992	16,314	Accidental poisoning	0
isoniazid —	1952	15,902	Paradoxical drug reaction	3
omega-3-acid ethyl esters —	2004	15,305	Blood triglycerides increased	3
acetaminophen and caffeine —	—	13,982	Migraine	0
memantine hydrochloride —	2003	13,824	Dementia	7
standardized senna concentrate —	—	13,716	Food allergy	0
triamterene —	1964	13,177	Chronic kidney disease	0
labetalol —	1984	12,988	Low birth weight baby	20
niacin —	1973	12,193	Flushing	17
felodipine —	1991	11,134	Vasculitis	4
metolazone —	1973	11,040	End stage renal disease	0
butalbital, acetaminophen, and caffeine —	—	10,538	Migraine	0
clobetasol propionate —	1994	10,007	Skin fissures	23
dorzolamide hydrochloride and timolol maleate —	—	8,434	Intraocular pressure increased	0
sevoflurane —	1995	7,843	Anaesthetic complication neurological	3
lamivudine and zidovudine —	—	7,700	Stillbirth	1
fluvastatin —	1993	7,469	Amaurosis fugax	4
repaglinide —	1997	7,285	Hypoglycaemic coma	2
ramelteon —	2005	7,280	Initial insomnia	0
triamterene capsules —	—	7,035	Chronic kidney disease	0
calcipotriene —	1993	6,619	Psoriasis	6
nabumetone —	1991	6,351	Chronic kidney disease	3
piroxicam —	1992	6,276	Duodenal ulcer perforation	2
triamterene and hydrochlorothiazide —	—	6,066	Oedema peripheral	0
potassium citrate —	1985	5,377	Product residue present	2
flecainide acetate tablet —	—	5,103	Electrocardiogram qrs complex prolonged	2
acitretin —	1996	4,791	Sensory loss	0
verapamil hydrochloride —	1984	4,229	Amaurosis fugax	0
dexmethylphenidate hydrochloride —	2001	4,152	Tic	0
amlodipine and atorvastatin —	—	4,056	Type 2 diabetes mellitus	0
sulfadiazine —	1941	3,863	Pulmonary vasculitis	2
acarbose —	1995	3,794	Hypoglycaemic coma	4
hydroxyzine pamoate —	1959	3,533	Respiratory arrest	4
desogestrel and ethinyl estradiol —	—	3,478	Muscle injury	6
ropinirole hydrochloride —	1997	3,404	Full blood count abnormal	1
pilocarpine hydrochloride —	1984	3,286	Vitreous floaters	5
galantamine —	2001	3,156	Sedation complication	2
sennosides 8.6 mg —	—	2,853	Constipation	0
silver sulfadiazine —	1973	2,245	Skin ulcer	1
meclizine hydrochloride chewable —	—	2,169	Vertigo	0
galantamine hydrobromide —	2001	1,632	Sedation complication	0
sodium polystyrene sulfonate —	1958	1,575	Nephrogenic anaemia	0
trimipramine —	1979	1,448	Pharyngitis	0
docusate sodium 50 mg and sennosides 8.6 mg —	—	784	Stomatitis	0

Recall history · 50 on record

Date	Class	Reason	Firm
Jun 2, 2026	III	Presence of foreign substance	ANI Pharmaceuticals, Inc.
May 29, 2026	II	Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.	Golden State Medical Supply Inc.
May 27, 2026	II	Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.	Lannett Company Inc.
Apr 29, 2026	II	CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit	Zydus Pharmaceuticals (USA) Inc
Apr 29, 2026	II	CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit	Zydus Pharmaceuticals (USA) Inc
Apr 9, 2026	II	Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.	The Harvard Drug Group LLC
Mar 20, 2026	II	CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.	Leading Pharma, LLC
Jan 10, 2026	II	Presence of Foreign Substance	Graviti Pharmaceuticals Private Limited
Nov 26, 2025	III	Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.	SUN PHARMACEUTICAL INDUSTRIES INC
Nov 18, 2025	III	Cross Contamination with Other Products	Glenmark Pharmaceuticals Inc., USA
Oct 20, 2025	II	Failed Dissolution Specifications	Golden State Medical Supply Inc.
Oct 10, 2025	II	Failed Dissolution Specifications	Lannett Company Inc.
Oct 10, 2025	II	Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .	The Harvard Drug Group LLC
Oct 10, 2025	II	Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .	The Harvard Drug Group LLC
Sep 19, 2025	II	Failed Dissolution Specifications	Ascend Laboratories, LLC
Sep 19, 2025	II	Failed Dissolution Specifications	Ascend Laboratories, LLC
Sep 19, 2025	II	Failed Dissolution Specifications	Ascend Laboratories, LLC
Sep 19, 2025	II	Failed Dissolution Specifications	Ascend Laboratories, LLC
Sep 3, 2025	II	Failed Impurities/Degradation Specifications	Glenmark Pharmaceuticals Inc., USA
Jun 19, 2025	II	Defective container; blister packaging inadequately sealed.	The Harvard Drug Group LLC
Jun 19, 2025	II	Defective container; blister packaging inadequately sealed.	The Harvard Drug Group LLC
May 27, 2025	II	CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.	Torrent Pharma Inc.
May 27, 2025	II	CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.	Torrent Pharma Inc.
Apr 22, 2025	II	CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.	RemedyRePack Inc.
Apr 18, 2025	II	cGMP Deviations	Preferred Pharmaceuticals, Inc.
Mar 24, 2025	II	CGMP Deviations	RemedyRepack Inc.
Mar 17, 2025	II	Failed dissolution specifications: lower than specifications	BIOCON PHARMA INC
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 13, 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
Mar 4, 2025	III	Cross Contamination	SUN PHARMACEUTICAL INDUSTRIES INC
Mar 4, 2025	III	Cross Contamination	SUN PHARMACEUTICAL INDUSTRIES INC
Feb 17, 2025	II	Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.	Safecor Health, LLC
Dec 27, 2024	II	Presence of Particulate Matter: A market complaint was received of a glass piece in the vial.	Eugia US LLC
Dec 17, 2024	II	Failed Dissolution Specifications:	Amerisource Health Services LLC
Dec 6, 2024	II	CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.	Aurobindo Pharma USA Inc
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Nov 1, 2024	II	cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.	Glenmark Pharmaceuticals Inc., USA
Oct 31, 2024	II	Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).	Noven Pharmaceuticals Inc
Sep 24, 2024	II	Presence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.	Nivagen Pharmaceuticals Inc
Jul 31, 2024	II	Presence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin Tablets	Granules Pharmaceuticals Inc.
Jul 26, 2024	II	Presence of Particulate Matter: Complaint received of a glass particle in the vial.	Eugia US LLC

Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.

Registration status

Some products from Bryant Ranch Prepack are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.